Equity Research
William Blair research analyst Brandon Vazquez was quoted in MedTech Dive’s coverage of biotech company Intuitive Surgical’s Q2 2023 earnings report.
“System unit placements were still ahead of expectations, which should be a positive indicator for future procedure growth especially when coupled with another quarter of higher than historical utilization growth,” Vazquez’s research note to investors said.
Stay up-to-date with the latest William Blair news and insights
Carson Dickson, CFA, a research analyst on our U.S. value equity team, discusses the outlook for agricultural equipment.
Watch the videoJayesh Kannan, CFA, explains the advancements India has made in its physical and digital infrastructure.
Watch the videoWilliam Blair initiated research coverage of Upstream Bio, Inc. (UPB $24.76), which is developing the differentiated TSLP receptor antibody verekitug for multiple inflammatory pulmonary diseases, including asthma and COPD.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
